Patients show 91% response to allogeneic CAR-T therapy
Drug Discovery World
OCTOBER 1, 2024
Investigators saw a 91% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (RRMM) following treatment with allogeneic CAR-T therapy P-BCMA-ALLO1 and lymphodepletion. The interim data from an ongoing Phase I trial in patients who have previously received three or more prior lines of therapy were presented at the 21 st International Myeloma Society (IMS) Annual Meeting in Rio de Janeiro.
Let's personalize your content